India and South Africa renew push for extending TRIPS waiver beyond Covid vaccines

22 March 2023
patent_innovation_money

Even as the World Trade Organization (WTO) members continue to remain divided on the waiver of intellectual property (IP) rights for Covid-related vaccine technologies, India, South Africa, and other developing countries have resuscitated their campaign to extend the temporary waiver of IP for Covid vaccines to coronavirus drugs at the WTO.

A temporary patent waiver was granted for five years by members of the WTO in June last year for the manufacture of Covid-19 vaccines. After six months, it was agreed to begin discussions regarding including therapeutics and diagnostics under the scope of this waiver, as proposed by India and South Africa.

India's Commerce and Industry Minister Piyush Goyal said the IP rights waiver for five years agreed upon during the 12th ministerial conference of the WTO would help developing countries manufacture patented Covid-19 vaccines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics